Terms ending in 2042
Every in-force patent on AstraZeneca AB's record whose computed term ends in 2042, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,109,310 | Exosome Extracellular Vesicles and Methods of Use AstraZeneca AB and Valadi, Hadi In force · High confidence | AstraZeneca AB and Valadi, Hadi | In force | High confidence | |
| US 12,668,785 | Combination Treatment by Administering a Recombinant Apyrase Protein in Conjunction with a P2Y12 Inhibitor In force · Medium confidence | AstraZeneca AB | In force | Medium confidence | |
| US 11,651,863 | Predicting Prostate Cancer Recurrence Using a Prognostic Model that Combines Immunohistochemical Staining and Gene Expression Profiling In force · High confidence | AstraZeneca Computational Pathology GmbH | In force | High confidence | |
| US 11,798,653 | Methods for Determining Treatment for Cancer Patients In force · High confidence | MedImmune, LLC | In force | High confidence | |
| US 11,845,791 | Antibodies Directed Against GDF-15 In force · High confidence | MedImmune, LLC | In force | High confidence | |
| US 11,883,582 | Inhaler In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 12,060,429 | Method of Treating Type 1 Interferon (IFN)-Mediated Disease Using a Subcutaneous Dosing Regimen Comprising Anifrolumab In force · Medium confidence | AstraZeneca AB | In force | Medium confidence | |
| US 12,620,146 | Graph Construction and Visualization of Multiplex Immunofluorescence Images In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 12,365,678 | Pharmaceutical process for the preparation of 4-{4-[(3R)-3-methylmorpholin-4-yl]-6-[1-((R)-S-methylsulfonimidoyl)cyclopropyl]pyrimidin-2-yl}-1H-pyrrolo[2,3-b] pyridine and intermediates In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 11,970,463 | Compounds and Their Use In force · High confidence | Tanabe Pharma Corporation | In force | High confidence | |
| 12 more term ends in 2042 · Pro | |||||
10 of 22 patents shown. Soonest term end first, then patent number.
Pro members see all 22.
16 of these are in force and held by AstraZeneca AB.
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.